Proteonomix, a developer of human cells based therapeutics, has licensed rights to use its anti-tumor technology.
The technology comprises methods for isolation and propagation of the primary human cells, gene profiles obtained from the cells identifying candidate micro RNAs and growth factor genes.
In addition, the technology includes methods for generating culture media conditioned by the cells for isolation of the inhibitory factors.
Proteonomix chief technology officer Steven Byle said recent experiments demonstrated the ability of the novel human cells and even the culture media conditioned by these cells to inhibit the proliferation of tumor cells, ultimately leading to their death.
"This technology has the potential to identify molecules that can kill tumor cells and provides insights into the potential delivery of these inhibitory factors in vivo," Byle added.